What Tyra Biosciences does

Tyra Biosciences is a clinical-stage biotechnology company developing next-generation precision medicines targeting FGFR biology in oncology and genetically defined conditions. The company was founded in 2018 and is headquartered in Carlsbad, California, listed on Nasdaq under the ticker TYRA since its 2021 IPO. Its core technology is the proprietary SNÅP Discovery Engine, an in-house structure-based drug design platform that produces full co-crystal structural "SNÅPshots" of drug-target interactions in as little as seven days, enabling angstrom-level medicinal chemistry iteration against a backdrop of hundreds of internally solved FGFR crystal structures.

The pipeline centers on three investigational oral FGFR inhibitors. The lead asset, dabogratinib (formerly TYRA-300), is a selective FGFR3 inhibitor designed to retain activity against the V555 gatekeeper resistance mutation and to avoid FGFR1-mediated off-target toxicity; it is being advanced concurrently in three Phase 2 studies under a "3x3" strategy: SURF302 in FGFR3-altered intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), SURF303 in low-grade upper tract urothelial carcinoma (LG-UTUC), and BEACH301 in pediatric achondroplasia. Two additional candidates — TYRA-430, an FGFR4/3-biased inhibitor in the Phase 1 SURF431 study for FGF19+/FGFR4-driven hepatocellular carcinoma, and TYRA-200, an FGFR1/2/3 inhibitor in the Phase 1 SURF201 study for FGFR2-altered cholangiocarcinoma — extend the platform.

The business is pre-revenue, funded entirely through capital markets, with no commercial product. As of Q1 2026, Tyra held $383.5M in cash and securities providing runway into the second half of 2028; R&D spend in Q1 2026 was $33.5M (up from $25.0M a year earlier) and full-year 2025 net loss was $119.9M. Commercial launch is anticipated post-approval, supported by a leadership team specifically built for rare-oncology and rare-disease commercialization.

Name

Tyra Biosciences

Legal name

Tyra Biosciences, Inc.

Website

https://tyra.bio/

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Tyra Biosciences is a clinical-stage biotech developing oral FGFR-selective precision medicines, led by dabogratinib (FGFR3) for bladder cancer, upper tract urothelial carcinoma, and pediatric achondroplasia, using its proprietary SNÅP structure-based drug design platform.

Ownership category

akta.pro rank

Product category

Precision Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industry

Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Precision oncology drugs
• FGFR kinase inhibitors
• Structure-based drug design
• Targeted cancer therapy
• Skeletal dysplasia therapeutics

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pre-revenue clinical-stage pipeline: Tyra Biosciences is a clinical-stage biotechnology company with no commercial product revenue. Net loss was $119.9 million for full-year 2025 and $39.3 million for Q1 2026, with R&D expenses increasing to $33.5 million from $25.0 million year-over-year. The company is funded by capital markets and expects no product revenue until regulatory approval and commercialization of dabogratinib, TYRA-200, or TYRA-430.
2. Capital markets financing (future R&D monetization): Pre-revenue biotech funded through equity financings including a $200 million private placement (Feb 2024), a $126 million at-the-market offering (March 2026), and prior IPO proceeds. These proceeds fund clinical development that will eventually translate to pharmaceutical product sales (likely one-time license / direct sales once approved).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Tyra Biosciences is a clinical-stage biotechnology company that develops investigational, oral small-molecule precision medicines targeting fibroblast growth factor receptor (FGFR) biology for oncology and genetically defined conditions. The company is advancing three drug candidates — dabogratinib (FGFR3-selective), TYRA-430 (FGFR4/3-biased), and TYRA-200 (FGFR1/2/3) — designed using its proprietary SNAP Discovery Engine to overcome acquired resistance and improve isoform selectivity relative to first-generation FGFR inhibitors.

Product overview

Tyra Biosciences is a clinical-stage biotechnology company that develops next-generation precision medicines using its proprietary SNAP Discovery Engine, a structure-based drug design platform built around hundreds of internally solved FGFR co-crystal structures. The company offers a focused portfolio of three investigational small-molecule precision oncology and skeletal-dysplasia drug candidates — the lead asset dabogratinib (formerly TYRA-300), a selective FGFR3 inhibitor being advanced in three Phase 2 studies (BEACH301 for achondroplasia, SURF302 for IR NMIBC, and SURF303 for LG-UTUC); TYRA-430, an FGFR4/3-biased inhibitor in the Phase 1 SURF431 study for FGF19+/FGFR4-driven hepatocellular carcinoma and other solid tumors; and TYRA-200, an FGFR1/2/3 inhibitor in the Phase 1 SURF201 study for FGFR2-altered cholangiocarcinoma and other solid tumors. Together, the SNAP engine and the three FGFR-targeted product candidates form an integrated precision-medicine platform targeting FGFR biology across oncology and genetically defined conditions.

Differentiator

Problem solved

Functional benefit

Brands

• dabogratinib: Lead product candidate, an investigational selective FGFR3 inhibitor formerly known as TYRA-300; being developed across skeletal dysplasia (achondroplasia), bladder cancer (NMIBC), and LG-UTUC indications.
• TYRA-430
• TYRA-200
• SNAP (SNÅP) Discovery Engine

Products and services

• Dabogratinib (formerly TYRA-300) Investigational oral, selective inhibitor of FGFR3 designed to maintain potency in the presence of treatment-emergent resistance mutations such as the V555 gatekeeper mutation and to be selective for FGFR3 over FGFR1/2 to limit off-target toxicity. Being developed for achondroplasia (BEACH301), intermediate-risk non-muscle invasive bladder cancer (SURF302), and low-grade upper tract urothelial carcinoma (SURF303).
• TYRA-430 Investigational oral FGFR4/3-biased inhibitor designed for FGF19+/FGFR4-driven cancers including advanced hepatocellular carcinoma (HCC), providing isoform-selective targeting. Currently in the SURF431 Phase 1 multicenter, open-label, first-in-human study.
• TYRA-200 Investigational oral FGFR1/2/3 inhibitor that has demonstrated in vitro potency against activating FGFR2 gene alterations and resistance mutations. Being evaluated in the SURF201 Phase 1 study for adults with unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors with activating FGFR2 alterations.

Quantifiable outcome

• Q1 2026 R&D expenses grew to $33.5 million from $25.0 million in Q1 2025, supporting advancement of three Phase 2 programs concurrently.
• +4 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Bladder Cancer Advocacy Network (BCAN)minorGTM or Marketing Partner · 21 May 2026Tyra Biosciences and BCAN collaborated to establish May 21 as UTUC Awareness Day to promote awareness and research for upper tract urothelial carcinoma (UTUC), a rare cancer affecting the kidneys and ureters. Tyra is conducting clinical trials with dabogratinib, an FGFR3 inhibitor, for low-grade UTUC, aiming to develop kidney-sparing treatments.
• University of Kansas Medical CentercoreStrategic or Co-development Partner · 6 May 2026The University of Kansas Medical Center is partnering with Tyra Biosciences on the SURF302 Phase 2 trial of dabogratinib (TYRA-300) in FGFR3-altered low-grade IR NMIBC, signaling external academic medical center confidence in Tyra's FGFR3-selective approach.

Scale indicators12 records

Recent moves1 record

Direct peers

• QED Therapeutics (BridgeBio Pharma): QED Therapeutics, a BridgeBio affiliate, is developing infigratinib (FGFR1-3 inhibitor) across the same FGFR3-driven oncology indications and pediatric achondroplasia, making it the closest direct competitor to Tyra's dabogratinib across both oncology and skeletal dysplasia programs.
• Relay Therapeutics: Relay Therapeutics is a precision oncology company developing RLY-4008 (lirafugratinib), a selective FGFR2 inhibitor for FGFR2-altered cholangiocarcinoma and other solid tumors — directly comparable to Tyra's TYRA-200 in mechanism, target patient population, and selective-kinase-inhibitor strategy.

Broad incumbents

• Johnson & Johnson (Janssen): J&J's Janssen markets Balversa (erdafitinib), the first FGFR kinase inhibitor approved, including for FGFR3-altered NMIBC — directly overlapping Tyra's lead indication and raising the competitive bar Tyra must beat on selectivity and tolerability.
• Incyte Corporation: Incyte markets Pemazyre (pemigatinib), an FGFR1-3 inhibitor approved for FGFR2-altered cholangiocarcinoma, directly competing with Tyra's TYRA-200 and representing a commercial-stage incumbent that Tyra must displace or outflank.
• Taiho Pharmaceutical (Otsuka): Taiho markets Lytgobi (futibatinib), an irreversible FGFR1-4 inhibitor approved for FGFR2 fusion-positive cholangiocarcinoma and designed to address resistance mutations including gatekeeper variants — a direct mechanistic competitor to dabogratinib's V555 differentiation thesis.
• Blueprint Medicines (Sanofi): Blueprint Medicines, now part of Sanofi, develops precision oncology kinase inhibitors (Ayvakit for PDGFRA/GIST) and rare-disease therapies using structure-based design. Their successful commercial playbook in rare oncology and team hiring into Tyra (CRO Heather Faulds ex-Blueprint) make Blueprint a directly comparable model for go-to-market and pipeline strategy.

Emerging players

• Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology company developing allosteric kinase inhibitors targeting oncogenic and resistance mutations, including in FGFR and other kinase families — sharing Tyra's strategy of designing against resistance mutations and structure-based inhibitor discovery.
• Cogent Biosciences: Cogent Biosciences is a clinical-stage precision oncology company developing selective kinase inhibitors (e.g., bezuclastinib for KIT-mutant GIST). It shares Tyra's model of structure-based, mutation-focused kinase-inhibitor development in oncology indications with limited treatment options.

Others

• Schrödinger, Inc. Schrödinger operates a computational drug discovery platform combining physics-based modeling with machine learning. While not a direct FGFR competitor, Schrödinger is highly comparable as a publicly traded platform-based drug discovery company using structural/precision methods to advance partnered and internal pipelines.
• Recursion Pharmaceuticals: Recursion is a clinical-stage AI-driven drug discovery company combining high-throughput biology with machine learning. While not kinase-focused, Recursion is comparable to Tyra as a publicly traded platform-enabled precision medicine company developing a multi-asset pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tyra-biosciences

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds5 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tyra Biosciences